Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

EQS-News: Benzinga / Key word (s): Science Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation ... from those evaluated in early-phase clinical trials to standard-care products for lymphoma, leukemia, and ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...

McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL ... such as BTK inhibitors, CAR T-cell therapy, antibody-drug conjugates, and ...

Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary ...

In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma ... as well as multiple early-stage programs ...